Comparative Pharmacology
Head-to-head clinical analysis: CEREBYX versus EPITOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEREBYX versus EPITOL.
CEREBYX vs EPITOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fosphenytoin is a prodrug of phenytoin, which stabilizes neuronal membranes by blocking voltage-gated sodium channels, thereby inhibiting repetitive firing of action potentials.
Carbamazepine stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting high-frequency repetitive firing of action potentials and reducing synaptic transmission.
Loading dose: 15-20 mg PE/kg IV/IM (max 1500 mg PE); maintenance: 4-6 mg PE/kg/day IV/IM divided q12h or q8h. Switch to oral phenytoin at equivalent dose.
Carbamazepine, immediate-release: initial 200 mg orally twice daily; increase by 200 mg/day at weekly intervals. Typical maintenance: 800-1200 mg/day in 2-3 divided doses. Extended-release: initial 200 mg orally twice daily; maintenance 400-600 mg twice daily.
None Documented
None Documented
The terminal elimination half-life of fosphenytoin (converted to phenytoin) is approximately 15 hours (range 10-20 hours) in adults with normal hepatic function; after conversion, phenytoin half-life is dose-dependent and averages 22 hours (range 7-42 hours) at therapeutic concentrations.
20-40 hours (mean 30 hours); linear kinetics at therapeutic doses; decreased with concomitant enzyme-inducing drugs
Renal excretion of unchanged drug and metabolites accounts for approximately 80% of the dose; about 20% is eliminated in feces via biliary excretion.
Renal: 70% (as glucuronide conjugates and other metabolites), Fecal: 30% (unchanged and metabolites)
Category C
Category C
Anticonvulsant
Anticonvulsant